中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝炎的诊治进展

蔡卫民

引用本文:
Citation:

非酒精性脂肪性肝炎的诊治进展

详细信息
  • 中图分类号: R575.1

Progress in the diagnosis and treatment of nonalcoholic steatohepatitis


  • [1]中华医学会肝脏病分会脂肪肝和酒精肝学组.非酒精性脂肪性肝病治疗指南[J].中华肝脏病杂志, 2006, 14 (3) ∶161~163.
    [1]中华医学会肝脏病分会脂肪肝和酒精肝学组.非酒精性脂肪性肝病治疗指南[J].中华肝脏病杂志, 2006, 14 (3) ∶161~163.
    [2]Wieckowska A, McCulloug AJ, and Feldstein AE.Noninvasive diag-nosis and montoring of nonalcoholic steatohepatitis:Present and fu-ture[J].Hepatology, 2007, 46 (2) ∶582~589.
    [2]Wieckowska A, McCulloug AJ, and Feldstein AE.Noninvasive diag-nosis and montoring of nonalcoholic steatohepatitis:Present and fu-ture[J].Hepatology, 2007, 46 (2) ∶582~589.
    [3]Baranova A, Younossi ZM.The future is around the corner:Nonin-vasie diagnosis of progressive nonalcoholic steatohepatitis[J].Hepa-tology, 2008, 47 (2) ∶373~375.
    [3]Baranova A, Younossi ZM.The future is around the corner:Nonin-vasie diagnosis of progressive nonalcoholic steatohepatitis[J].Hepa-tology, 2008, 47 (2) ∶373~375.
    [4]万燕萍, 徐仁应, 方华, 等.上海地区1180名在校儿童非酒精性脂肪性肝病检出率及危险因素分析[J].中华肝脏病杂志, 2007, 15 (9) ∶644~653.
    [4]万燕萍, 徐仁应, 方华, 等.上海地区1180名在校儿童非酒精性脂肪性肝病检出率及危险因素分析[J].中华肝脏病杂志, 2007, 15 (9) ∶644~653.
    [5]Ekstedt M, Franzen LE, Mathiesen UL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatolo-gy, 2006, 44 (4) ∶865~873.
    [5]Ekstedt M, Franzen LE, Mathiesen UL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatolo-gy, 2006, 44 (4) ∶865~873.
    [6]Yamazaki Y, Kakizaki S, Horiguchi N, et al.The role of the nuclearreceptor constitutive androstane receptor in the pathogenesis of non-alocholic steatohepatitis[J].Gut, 2007, 56 (4) ∶565~574.
    [6]Yamazaki Y, Kakizaki S, Horiguchi N, et al.The role of the nuclearreceptor constitutive androstane receptor in the pathogenesis of non-alocholic steatohepatitis[J].Gut, 2007, 56 (4) ∶565~574.
    [7]Mofrad P, Contos MJ, Haque M, et al.Clinical and histologic spec-trum of nonalcoholic fatty liver disease associated with normal ALTvalues[J].Hepatology, 2003, 37 (4) ∶1286~1292.
    [7]Mofrad P, Contos MJ, Haque M, et al.Clinical and histologic spec-trum of nonalcoholic fatty liver disease associated with normal ALTvalues[J].Hepatology, 2003, 37 (4) ∶1286~1292.
    [8]Kunde SS, Lazenby AJ, Clements RH, et al.Spectum of NAFLSand diagnostic implications of the proposed newnormal range for ser-um ALTin obese women[J].Hepatology, 2005, 42 (2) ∶650~656.
    [8]Kunde SS, Lazenby AJ, Clements RH, et al.Spectum of NAFLSand diagnostic implications of the proposed newnormal range for ser-um ALTin obese women[J].Hepatology, 2005, 42 (2) ∶650~656.
    [9]Angulo P, Keach JC, Batts KP, et al.Independent predictors of liv-er fibrosis in patients with nonalcoholic steatohepatitis[J].Hepatolo-gy, 1999, 30 (5) ∶1356~1362.
    [9]Angulo P, Keach JC, Batts KP, et al.Independent predictors of liv-er fibrosis in patients with nonalcoholic steatohepatitis[J].Hepatolo-gy, 1999, 30 (5) ∶1356~1362.
    [10]Bonnefont-Rousselot D, Ratziu V, Giral P, et al.Blood oxidativestress markers are unreliable markers of hepatic steatosis[J].AlimentPharmacol Ther, 2006, 23 (1) ∶91~98.
    [10]Bonnefont-Rousselot D, Ratziu V, Giral P, et al.Blood oxidativestress markers are unreliable markers of hepatic steatosis[J].AlimentPharmacol Ther, 2006, 23 (1) ∶91~98.
    [11]Solga SF, Alkhuraishe A, Cope K, et al.Breath biomarkers andnon-alcoholic fatty liver disease:preliminary observations[J].Bio-markers, 2006, 11 (1) ∶174~183.
    [11]Solga SF, Alkhuraishe A, Cope K, et al.Breath biomarkers andnon-alcoholic fatty liver disease:preliminary observations[J].Bio-markers, 2006, 11 (1) ∶174~183.
    [12]Abirus S, Migita K, Macda Y, et al.Serum cytokine and solublecytokine receptor levels in patients with[J].NASHLiver Int, 2006, 26 (1) ∶39~45.
    [12]Abirus S, Migita K, Macda Y, et al.Serum cytokine and solublecytokine receptor levels in patients with[J].NASHLiver Int, 2006, 26 (1) ∶39~45.
    [13]Haukeland JW, Damas JK.Konopski Z, et al.Systemic inflamma-tion in NAFLD is characteriged by elevated levels of CCL2[J].Hep-atology, 2006, 44 (5) ∶1167~1174.
    [13]Haukeland JW, Damas JK.Konopski Z, et al.Systemic inflamma-tion in NAFLD is characteriged by elevated levels of CCL2[J].Hep-atology, 2006, 44 (5) ∶1167~1174.
    [14]Fukuhara A, Matsuda M, Nishizawa M, et al.Visfatin:a proteinsecreted by visceral fat that mimics the effects of insulin[J].Sci-ence, 2005, 307 (2) ∶426~430.
    [14]Fukuhara A, Matsuda M, Nishizawa M, et al.Visfatin:a proteinsecreted by visceral fat that mimics the effects of insulin[J].Sci-ence, 2005, 307 (2) ∶426~430.
    [15]Yang Q, Graham TE, Mody N, et al.Serum retinol binding protein4 contributes to insulin resistance in obestity and type 2 diabetes[J].Nature, 2005, 436 (2) ∶356~362.
    [15]Yang Q, Graham TE, Mody N, et al.Serum retinol binding protein4 contributes to insulin resistance in obestity and type 2 diabetes[J].Nature, 2005, 436 (2) ∶356~362.
    [16]Gulsen M, Yesilova Z, Bagci S, et al.Elevated plasma homocys-teine concentrations as a predictor of steatohepatitis in patients withNAFLD[J].Hepatology, 2005, 20 (5) ∶1448~1455.
    [16]Gulsen M, Yesilova Z, Bagci S, et al.Elevated plasma homocys-teine concentrations as a predictor of steatohepatitis in patients withNAFLD[J].Hepatology, 2005, 20 (5) ∶1448~1455.
    [17]Yesilova Z, Oktenli C.Increased acylatin stimulating protein con-centration in NAFLD are associated with insulin resistance[J].Am JGastroenterol, 2005, 100 (2) ∶842~846.
    [17]Yesilova Z, Oktenli C.Increased acylatin stimulating protein con-centration in NAFLD are associated with insulin resistance[J].Am JGastroenterol, 2005, 100 (2) ∶842~846.
    [18]Rodriguez-Hernadez H, Gonzalez JL.Hypomagnesmia in sulin re-sistance and NAFLD steatohepatitis in obese subjects[J].Arch MedRes, 2005, 36 (2) ∶362~366.
    [18]Rodriguez-Hernadez H, Gonzalez JL.Hypomagnesmia in sulin re-sistance and NAFLD steatohepatitis in obese subjects[J].Arch MedRes, 2005, 36 (2) ∶362~366.
    [19]Wieckowska A, Zein NN, Yerian LM, et al.In vivo assessment ofliver cell apoptosis as a novel biomarker of disease severity in nonal-coholic fatty liver disease[J].Hepatology, 2006, 44 (1) ∶27~33.
    [19]Wieckowska A, Zein NN, Yerian LM, et al.In vivo assessment ofliver cell apoptosis as a novel biomarker of disease severity in nonal-coholic fatty liver disease[J].Hepatology, 2006, 44 (1) ∶27~33.
    [20]Rosenberg WM, Voelker M, Thiel R, et al.Serum markers detectthe presence of liver fibrosis:acohort study[J].Gastroenterology, 2004, 127∶1704~1713.
    [20]Rosenberg WM, Voelker M, Thiel R, et al.Serum markers detectthe presence of liver fibrosis:acohort study[J].Gastroenterology, 2004, 127∶1704~1713.
    [21]Guha IN, Parkes J, Roderick P, et al.Noninvasive marker of fibro-sis in NAFLD:Valicatine the Eouropean Liver Fibrosis Panel and ex-ploring simple markers[J].Hepatology, 2008, 47 (2) ∶455~460.
    [21]Guha IN, Parkes J, Roderick P, et al.Noninvasive marker of fibro-sis in NAFLD:Valicatine the Eouropean Liver Fibrosis Panel and ex-ploring simple markers[J].Hepatology, 2008, 47 (2) ∶455~460.
    [22]Foucher J, Castera L, Bernard PH, et al.Prevalence and factorsassociated with failure of liver stiffness measurement using FibroScanin a prospective study of 2114 examinations[J].Eur J GastroenterolHepatol, 2006, 18 (2) ∶411~412.
    [22]Foucher J, Castera L, Bernard PH, et al.Prevalence and factorsassociated with failure of liver stiffness measurement using FibroScanin a prospective study of 2114 examinations[J].Eur J GastroenterolHepatol, 2006, 18 (2) ∶411~412.
    [23]Kim KM, Choi WB, Park SH, et al.Diagnosis of hepatic steatosisand fibrosis by transient elastograph in asymptomatic healthy imdivid-ual:a prospective study of living related potential liver donots[J].JGastroenterol, 2007, 42 (1) ∶382~388.
    [23]Kim KM, Choi WB, Park SH, et al.Diagnosis of hepatic steatosisand fibrosis by transient elastograph in asymptomatic healthy imdivid-ual:a prospective study of living related potential liver donots[J].JGastroenterol, 2007, 42 (1) ∶382~388.
    [24]Cobbold JFL, Taylor-Robinson SD.Transient elastography in a-cute hepatitis:All that's stiff is no fibrosis[J].Hepatology, 2008, 47 (2) ∶370~372.
    [24]Cobbold JFL, Taylor-Robinson SD.Transient elastography in a-cute hepatitis:All that's stiff is no fibrosis[J].Hepatology, 2008, 47 (2) ∶370~372.
    [25]Romero-Gomeg M, Gomeg-Gongaleg E, Madrago A, et al.Op-tical analysis of computed tomography images of the liver predicts fi-brosis stage and distribution in chronic Hepatitis C[J].Hepatology, 2008, 47 (2) ∶810~816.
    [25]Romero-Gomeg M, Gomeg-Gongaleg E, Madrago A, et al.Op-tical analysis of computed tomography images of the liver predicts fi-brosis stage and distribution in chronic Hepatitis C[J].Hepatology, 2008, 47 (2) ∶810~816.
    [26]Talwalkar JA, Yin M, Fidler JL, et al.Magnetic resonance imagingof hepatic fibrosis:Emerging clinical applications[J].Hepatology, 2008, 47 (1) ∶332~342.
    [26]Talwalkar JA, Yin M, Fidler JL, et al.Magnetic resonance imagingof hepatic fibrosis:Emerging clinical applications[J].Hepatology, 2008, 47 (1) ∶332~342.
    [27] 吴苾, 朱彬, 周翔平, 等.慢性病毒肝炎患者磁共振31P波谱与病理关系[J].中华肝脏病杂志, 2007, 15 (5) ∶338.
    [27] 吴苾, 朱彬, 周翔平, 等.慢性病毒肝炎患者磁共振31P波谱与病理关系[J].中华肝脏病杂志, 2007, 15 (5) ∶338.
    [28]Schwimmer JB, Deutsch R, Kahen T, et al.Prevalence of fatty liv-er in children and adolescent[J].Pediatrics, 2006, 118 (11) ∶1388~1393.
    [28]Schwimmer JB, Deutsch R, Kahen T, et al.Prevalence of fatty liv-er in children and adolescent[J].Pediatrics, 2006, 118 (11) ∶1388~1393.
    [29]Ratziu V, Charlotte F, Heurtier A, et al.Sampling variability of liv-er biopsy in nonalcoholic fatty liver disease[J].Gastroenterology, 2005, 128 (7) ∶1898~1906.
    [29]Ratziu V, Charlotte F, Heurtier A, et al.Sampling variability of liv-er biopsy in nonalcoholic fatty liver disease[J].Gastroenterology, 2005, 128 (7) ∶1898~1906.
    [30]Brunt EM.Do you see what I see?The role of quality histopathologyin scientific study[J].Hepatology, 2008, 47 (3) ∶771~774.
    [30]Brunt EM.Do you see what I see?The role of quality histopathologyin scientific study[J].Hepatology, 2008, 47 (3) ∶771~774.
    [31]Baranova A, Liotta, Petricoin E, et al.The role of genomics andproteomics technologies in studying non-alcoholic fatty liverdisease[J].Clin Liv Dis, 2007, 11 (1) ∶207~220.
    [31]Baranova A, Liotta, Petricoin E, et al.The role of genomics andproteomics technologies in studying non-alcoholic fatty liverdisease[J].Clin Liv Dis, 2007, 11 (1) ∶207~220.
    [32]Huang H, Shiffman ML, Cheung RC, et al.Identification of twogene variant associated with risk of advanced fibrosis in patiens withchronic Phepatitis C[J].Gastroenterology, 2006, 130∶1679-1687.
    [32]Huang H, Shiffman ML, Cheung RC, et al.Identification of twogene variant associated with risk of advanced fibrosis in patiens withchronic Phepatitis C[J].Gastroenterology, 2006, 130∶1679-1687.
    [33]Huang H, Shiffman ML, friedmen S, et al.A7 gene Signateere i-dentifies the risk of developing cirrhosis in patients with chronic hep-atitis C[J].Hepatology, 2007, 46 (2) ∶297-306.
    [33]Huang H, Shiffman ML, friedmen S, et al.A7 gene Signateere i-dentifies the risk of developing cirrhosis in patients with chronic hep-atitis C[J].Hepatology, 2007, 46 (2) ∶297-306.
    [34]Zhen M, Cai WM, Zhao JK, et al.Determination of serumlevels ofYKL-40 and hyaluroinic acid in patients with hepatic fibro sis dusto schistosomiasis japonica and appraisal of their chinical value[J].Acta Tropica, 2005, 96 (3) ∶148-152.
    [34]Zhen M, Cai WM, Zhao JK, et al.Determination of serumlevels ofYKL-40 and hyaluroinic acid in patients with hepatic fibro sis dusto schistosomiasis japonica and appraisal of their chinical value[J].Acta Tropica, 2005, 96 (3) ∶148-152.
    [35]Lai KKY, Klippakkam D, Beretta L.Comprehensive and quantita-tive proteome profiling of mouse liver and plasma[J].Hepatology, 2008, 47 (3) ∶1043~1051.
    [35]Lai KKY, Klippakkam D, Beretta L.Comprehensive and quantita-tive proteome profiling of mouse liver and plasma[J].Hepatology, 2008, 47 (3) ∶1043~1051.
    [36]黄炜木焱, 范建高, 陈力元.非酒精性脂肪性肝病的治疗[J].中华肝脏病杂志, 2007, 15 (9) ∶687~688.
    [36]黄炜木焱, 范建高, 陈力元.非酒精性脂肪性肝病的治疗[J].中华肝脏病杂志, 2007, 15 (9) ∶687~688.
    [37]George J.Non-alcoholic steatohepatitis:Concepts on pathogenesisand therapy[R].Falk Symposium163, 2008, 49~50.
    [37]George J.Non-alcoholic steatohepatitis:Concepts on pathogenesisand therapy[R].Falk Symposium163, 2008, 49~50.
    [38]Caldwell SH, Argo CK.Divergent effects of penoxisome proliferator-activated receptor-r ligands in human and mouee nonalcoholicsteatohepatitis[J].Hepatology, 2007, 46 (2) ∶285-287.
    [38]Caldwell SH, Argo CK.Divergent effects of penoxisome proliferator-activated receptor-r ligands in human and mouee nonalcoholicsteatohepatitis[J].Hepatology, 2007, 46 (2) ∶285-287.
    [39]Tahan V, Imerya Z N, Avsar E, et al.Effects of rosiglitazone on me-thionine-choline diet-induced nonalcoholic eteatohepatitivs[J].Hepatology, 2007, 46 (6) ∶2045.
    [39]Tahan V, Imerya Z N, Avsar E, et al.Effects of rosiglitazone on me-thionine-choline diet-induced nonalcoholic eteatohepatitivs[J].Hepatology, 2007, 46 (6) ∶2045.
    [40]Aithal GP, Thomas JA, Koye D, et al.A romdomi ged, doubleblind, placebo comtrolled trial of one year of pioglitagone in non-di-abetic subjects with noalcoholic steatohepatitis[J].Hepatology, 2007, 46 (4, Suppl) ∶295A.
    [40]Aithal GP, Thomas JA, Koye D, et al.A romdomi ged, doubleblind, placebo comtrolled trial of one year of pioglitagone in non-di-abetic subjects with noalcoholic steatohepatitis[J].Hepatology, 2007, 46 (4, Suppl) ∶295A.
    [41]Nakano R, kurasaki E, Shimaya A, et al.Antagonism of PPARrprevents high-fat diet-induced obesity in vivo[J].Biochemicalpharmacology, 2006, 72 (1) ∶42-52.
    [41]Nakano R, kurasaki E, Shimaya A, et al.Antagonism of PPARrprevents high-fat diet-induced obesity in vivo[J].Biochemicalpharmacology, 2006, 72 (1) ∶42-52.
    [42]Wasmuth HE, Trartwein C.CB1 cannabinoid receptor antagonism:A new strategy for the treatment of liver fibrosis[J].Hepatology, 2007, 45 (2) ∶543-545.
    [42]Wasmuth HE, Trartwein C.CB1 cannabinoid receptor antagonism:A new strategy for the treatment of liver fibrosis[J].Hepatology, 2007, 45 (2) ∶543-545.
    [43]Teixeira-clerc F, Julien B, Grenard P, et al.CB1cannabinoid re-ceptor antagonism:a new strategy for the treatment of liverfibrosis[J].Nat Med, 2006, 15∶671~676.
    [43]Teixeira-clerc F, Julien B, Grenard P, et al.CB1cannabinoid re-ceptor antagonism:a new strategy for the treatment of liverfibrosis[J].Nat Med, 2006, 15∶671~676.
    [44]Weiskirchen R, Meurer SK.Bone morphogenetic protein-7 in fo-cus:Amember of the TGFβsuperfamily is implicated in the mainter-ance of liver health[J].Hepatology, 2007, 45 (5) ∶1324-1325.
    [44]Weiskirchen R, Meurer SK.Bone morphogenetic protein-7 in fo-cus:Amember of the TGFβsuperfamily is implicated in the mainter-ance of liver health[J].Hepatology, 2007, 45 (5) ∶1324-1325.
    [45]Gressner OA, weiskirchen R, Gressner AM.Evalving concepts ofliver fibrogenesis provid new diagnostic and therapeutic options[J].Comparative Hepatology, 2007, 6 (1) ∶7-15.
    [45]Gressner OA, weiskirchen R, Gressner AM.Evalving concepts ofliver fibrogenesis provid new diagnostic and therapeutic options[J].Comparative Hepatology, 2007, 6 (1) ∶7-15.
    [46]黄宁, 曾金兰, 李淑莉, 等.TGF-β1、BMP-7 mRNA在实验性肝纤维化中的表达及意义[J].微循环学杂志, 2007, 17 (3) ∶19~21.
    [46]黄宁, 曾金兰, 李淑莉, 等.TGF-β1、BMP-7 mRNA在实验性肝纤维化中的表达及意义[J].微循环学杂志, 2007, 17 (3) ∶19~21.
    [47]Zou C, Ma J, Wang X, et al.Lack of Fas antagonism by Met inhuman fatty liver disease[J].Nat Med, 2007, Sep;13∶1078.
    [47]Zou C, Ma J, Wang X, et al.Lack of Fas antagonism by Met inhuman fatty liver disease[J].Nat Med, 2007, Sep;13∶1078.
    [48]Kroy D.“Peptide-based NASH therapy, A first crucial.Step-Soon clinical reality?”[J].Hepatology, 2008, 47 (2) ∶757~758.
    [48]Kroy D.“Peptide-based NASH therapy, A first crucial.Step-Soon clinical reality?”[J].Hepatology, 2008, 47 (2) ∶757~758.
    [49]Yamaguchi K, Yang L, McCall S, et al.Diacylgly cerol acyltran-ferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in micewith NASH[J].Hepatology, 2008, 47 (2) ∶625~635.
    [49]Yamaguchi K, Yang L, McCall S, et al.Diacylgly cerol acyltran-ferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in micewith NASH[J].Hepatology, 2008, 47 (2) ∶625~635.
    [50]Caligiuri A, Bertolani C, Guerra CT, et al.Adenosine monophos-phate-activated protein dinase modulates the activated phenotype ofhaepatic stellate cells[J].Hepatology, 2005, 47 (2) ∶668~676.
    [50]Caligiuri A, Bertolani C, Guerra CT, et al.Adenosine monophos-phate-activated protein dinase modulates the activated phenotype ofhaepatic stellate cells[J].Hepatology, 2005, 47 (2) ∶668~676.
    [51]Adachi M, Brenner DA.High molecular weight adiponectin inhibitsproliferation of hepatic stellale cell via actvation of AMPK[J].Hepa-tology, 2008, 47 (2) ∶667~685.
    [51]Adachi M, Brenner DA.High molecular weight adiponectin inhibitsproliferation of hepatic stellale cell via actvation of AMPK[J].Hepa-tology, 2008, 47 (2) ∶667~685.
    [52]Sancho-bru P, Bataller R, Fernandez-Varo G, et al.Brady-kinkin attenuates hepatocellular damage and fibrosis in rat with chro-nic liver injury[J].Gastroenterology, 2007, 133 (6) ∶2019~2028.
    [52]Sancho-bru P, Bataller R, Fernandez-Varo G, et al.Brady-kinkin attenuates hepatocellular damage and fibrosis in rat with chro-nic liver injury[J].Gastroenterology, 2007, 133 (6) ∶2019~2028.
  • 加载中
计量
  • 文章访问数:  2363
  • HTML全文浏览量:  14
  • PDF下载量:  870
  • 被引次数: 0
出版历程
  • 出版日期:  2009-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回